Dolutegravir

Published November 04, 2012; Updated December 2017
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-03
Selected Reference
6. Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. In: Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle. Abstract 44LB.